
Scribe closes $100M series B round for gene editing rewrite
BioWorld
|
March 31, 2021
X min read
BioWorld
|
March 31, 2021
Share on Social
More like this
Media
Scribe Therapeutics to Participate in Upcoming Healthcare Investor Conferences
November 5, 2026
Read Now
Press
Scribe Therapeutics to Participate in Upcoming Healthcare Investor Conferences
November 5, 2026
Read Now
Media
Scribe Therapeutics to Present Updated Data on PCSK9-Targeting Epigenetic Silencing and LPA-Targeting Gene Editing Programs at American Heart Association (AHA) Scientific Sessions 2026
November 4, 2026
Read Now
Press
Scribe Therapeutics to Present Updated Data on PCSK9-Targeting Epigenetic Silencing and LPA-Targeting Gene Editing Programs at American Heart Association (AHA) Scientific Sessions 2026
November 4, 2026
Read Now